#United States #Ibezapolstat #C. difficile #Staten Island #Acurx Pharmaceuticals

Acurx Pharmaceuticals Makes Waves at International C. difficile Symposium

Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company, recently presented significant findings regarding their innovative antibiotic, Ibezapolstat, during the 9th International C. difficile Symposium held from September 8-10, 2026 in Bled, Slovenia. The presentation was made by Dr. Eugenie Bassères from the University of Houston College of Pharmacy, highlighting Ibezapolstat's superior in vitro kill kinetics in comparison to established treatments like voncomycin and fidaxomicin.

Background on Ibezapolstat

Ibezapolstat is a member of a new class of antibiotics aimed at combating difficult-to-treat bacterial infections. Notably, it has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, allowing it to benefit from expedited development processes under the Generating New Antibiotic Incentives Now (GAIN) Act.

The study focused on the recurrent infections caused by Clostridioides difficile (C. difficile), particularly in environments where vancomycin-resistant Enterococcus (VRE) is present. It is well-known that the microbiome of patients suffering from recurrent C. difficile infections often displays an overgrowth of Enterococcus species, leading to challenges in treatment.

Study Findings

The comparative study revealed that Ibezapolstat (IBZ) maintained a remarkable level of bactericidal activity under co-culture conditions with C. difficile and VRE, outperforming the antibiotics considered standard of care. The results indicated that whereas all VRE strains were highly resistant to vancomycin, both IBZ and fidaxomicin presented significantly lower susceptibility thresholds. Notably, Ibezapolstat’s performance yielded a 5.51-log reduction in C. difficile count in co-culture, showcasing its effectiveness against antibiotic-resistant bacteria. Moreover, it was noted that while the presence of C. difficile minimally impaired the killing efficacy of VRE, IBZ and fidaxomicin exhibited robust activity against VRE.

Dr. Kevin Garey, the Principal Investigator of the study, remarked on the significance of the findings: “These new data support ibezapolstat's unique antibacterial activity against C. difficile while maintaining a healthy microbiome.” Moreover, the study highlighted that Ibezapolstat did not promote overgrowth of vancomycin-resistant strains, a crucial factor in treatment effectiveness.

Implications for Future Treatments

According to Robert J. DeLuccia, Executive Chairman of Acurx, the research bolsters confidence in Ibezapolstat's usability in clinical settings. “If these findings hold true through our Phase 3 clinical trials, we could significantly aid in reducing the risk posed by VRE while treating CDI.”

Acurx is planning a Phase 3 registration program for Ibezapolstat, which might pave the way for clinical use that could revolutionize treatment protocols for C. difficile. The Phase 3 trial aims to recruit approximately 550 patients and will pit Ibezapolstat against standard treatment options. Positive results from this trial could ultimately help in gaining FDA approval for market distribution.

Additional Future Trials

Aside from the upcoming trials, Acurx has also initiated a clinical trial aimed at patients with multiply recurrent CDI, examining the efficacy of Ibezapolstat in patients who have suffered multiple episodes. This trial is crucial as it lays groundwork for potential future treatments and innovative therapeutic protocols.

Conclusion

The findings presented at the International C. difficile Symposium underscore the potential of Ibezapolstat to become a leading treatment for patients facing recurrent CDI, particularly where conventional treatments have begun to fail. As the company moves forward, the medical community watches with anticipation, hoping that Ibezapolstat will not just be another antibiotic, but a transformative solution in the fight against resistant bacterial infections.